Nirsevimab awarded Promising Innovative Medicine (PIM) status for the prevention of respiratory syncytial virus (RSV) associated lower respiratory tract

The MHRA have awarded PIM status for this extended half-life monoclonal antibody on the basis of phase IIb results, which found a significant reduction in medically attended lower respiratory tract infection due to RSV in healthy preterm infants vs placebo.

Source:

PharmaTimes